Conversion of ヴァックスラボ into a Consolidated Subsidiary
First written in FY2019-Q1. 3 of 4 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019RestatedAnnual report
「Vaxslab Co., Ltd., which was an unconsolidated subsidiary in the previous fiscal year, has been included in the scope of consolidation because its materiality has increased.」
The company has reaffirmed the consolidation of Vaxslab in the full-year scope of consolidation due to its increased materiality. - FY2019-Q3RestatedAnnual report
「Due in part to the inclusion of Vaxslab Co., Ltd. in the scope of consolidation from the first quarter, orders received were ¥38.07 billion, up 2.8% year on year, and revenue was ¥33.83 billion, up 7.8%. Operating profit also rose 66.2% to ¥2.07 billion, as the NTT business progressed strongly.」
The company has reaffirmed the consolidation of Vaxslab from the first quarter and the performance of the Tsuken Group, including its impact. - FY2019-Q2RestatedAnnual report
「From the first quarter, Vaxslab Co., Ltd., previously an unconsolidated subsidiary, has been included in the scope of consolidation because its materiality has increased.」
The company has reaffirmed Vaxslab's consolidation due to its increased materiality and the resulting total of 41 consolidated subsidiaries. - FY2019-Q1First statedAnnual report
「From the first quarter of the current fiscal year, Vaxslab Co., Ltd., previously an unconsolidated subsidiary, has been included in the scope of consolidation because its materiality has increased.」
Vaxslab was added to the scope of consolidation due to its increased materiality, bringing the number of consolidated subsidiaries after the change to 41.